Journal
JOURNAL OF HEALTHCARE ENGINEERING
Volume 2022, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2022/4033373
Keywords
-
Categories
Ask authors/readers for more resources
This study found that miR-139-5p inhibits the proliferation and metastasis of gastric cancer cells through downregulating TPD52. It also found that low expression of miR-139-5p is associated with adverse clinical features and prognosis in gastric cancer patients.
Background. Many researchers have confirmed that miRNAs are involved in the pathogenesis of gastric cancer (GC). This study focused on investigating the specific functions of miR-139-5p in GC. Methods. MiR-139-5p and TPD52 expressions were observed by qRT-PCR or western blot in GC. The functional mechanism of miR-139-5p was explored by the luciferase reporter assay, transwell assay, and MTT assay. Results. MiR-139-5p downregulation and TPD52 upregulation were detected in GC. Adverse clinical features and prognosis in GC patients were related to low miR-139-5p expression. MiR-139-5p overexpression restrained GC cell proliferation and metastasis. Furthermore, miR-139-5p directly targeted TPD52. TPD52 silencing blocked GC progression. And TPD52 upregulation weakened the antitumor effect of miR-139-5p in GC. Conclusion. MiR-139-5p inhibits GC cell proliferation and metastasis through downregulating TPD52.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available